The growing importance of PON1 in cardiovascular health: A review

Journal of Cardiovascular Medicine

Volumn 13, Issue 7, 2012, Pages 443-453

  MacHaria, Muiruri ^a   Hassan, Mogamat S ^b   Blackhurst, Diane ^c   Erasmus, Rajiv T ^a   Matsha, Tandi E ^d  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b CAPE PENINSULA UNIVERSITY OF TECHNOLOGY   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d Department of Biomedical Sciences   (South Africa)

Author keywords

atherosclerosis; cardiovascular disease; paraoxonase 1; PON1 polymorphisms; PON1 status

Indexed keywords

ANTIOXIDANT; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 2; ATORVASTATIN; BEZAFIBRATE; CALCIUM; CIPROFIBRATE; CLOFIBRIC ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLUCONOLACTONASE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE THIOLACTONE; HYDROLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; PARAOXONASE 3; PROBUCOL; ROSIGLITAZONE; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TETRAHYDROLIPSTATIN; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIETARY INTAKE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME SPECIFICITY; GENETIC POLYMORPHISM; HIGH RISK PATIENT; HUMAN; HYDROLYSIS; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE; LIPID METABOLISM; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; METABOLITE; NONHUMAN; OXIDATION; REVIEW; THEORETICAL STUDY;

ANIMALS; ARYLDIALKYLPHOSPHATASE; CARDIOVASCULAR DISEASES; DIET; DISEASE MODELS, ANIMAL; HUMANS; HYPOLIPIDEMIC AGENTS; LIFE STYLE; LIPID METABOLISM; MICE; POLYMORPHISM, GENETIC;

EID: 84862522720     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e328354e3ac     Document Type: Review

References (174)

1. The World Health Organization. Global atlas on cardiovascular disease prevention and control: policies, strategies and interventions, 2011 available: http://www.who.int/cardiovascular-diseases/en/ cvd-atlas13coronaryHD.pd.f.
2. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54:2129-2138.
3. Mackness B, Mackness M. High-density lipoprotein: why all the fuss? Ann Clin Biochem 2009; 46:5-7.
4. Sesal C, Ciloglu F, Peker I, Sayar N. Role of angiotensin converting enzyme, paraoxonase 155, 192 gene polymorphisms in syndrome X and coronary heart disease. Pak J Biol Sci 2009; 12:46-51.
5. Ayub A, Mackness M, Arrol S, et al. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19:330-335. (Pubitemid 29072747)
6. Kerkeni M, Addad F, Chauffert M, et al. Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease. Clin Biochem 2006; 39:821-825. (Pubitemid 44201194)
7. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci (Lond) 2004; 107:435-447. (Pubitemid 39506735)
8. Mackness B, Durrington PN, Abuashia B, et al. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci 2000; 98:355-363. (Pubitemid 30145243)
9. Suvarna R, Rao SS, Joshi C, et al. Paraoxonase activity in type 2 diabetes mellitus patients with and without complications. J Clin Diagn Res 2011; 5:63-65; 64.
10. Boemi M, Leviev I, Sirolla C, et al. Serum paraoxonase is reduced in type 1 diabetic patients compared to nondiabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis 2001; 155:229-235. (Pubitemid 32167144)
11. Shih DM, Gu L, Xia YR, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394:284-287. (Pubitemid 28335041)
12. Ng DS, Chu T, Esposito B, et al. Paraoxonase-1 deficiency in mice predisposes to vascular inflammation, oxidative stress, and thrombogenicity in the absence of hyperlipidemia. Cardiovasc Pathol 2008; 17:226-232. (Pubitemid 351978278)
13. Fuhrman B, Gantman A, Aviram M. Paraoxonase 1 (PON1) deficiency in mice is associated with reduced expression of macrophage SR-BI and consequently the loss of HDL cytoprotection against apoptosis. Atherosclerosis 2010; 211:61-68.
14. Rozenberg O, Rosenblat M, Coleman R, et al. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies inPON1-knockout mice. Free Radic Biol Med 2003; 34:774-784. (Pubitemid 36288542)
15. Mazur A. An enzyme in animal tissues capable of hydrolyzing the phosphorus-fluorine bond of alkyl fluorophospates. J Biol Chem 1946; 164:271-289.
16. Aldridge WN. Serum esterases. II. An enzyme hydrolyzing diethyl p-nitrophenyl phosphate (E600) and its identity with the A-esterase of mammalian sera. Biochem J 1953; 53:117-124.
17. Costa LG, Cole TB, Vitalone A, Furlong CE. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin Chim Acta 2005; 37-47. (Pubitemid 40093856)
18. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein.FEBSLett 1991; 286:152-154.
19. Primo-Parma SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996; 33:498-509.
20. Mochizuki H, Scherer SW, Xi T, et al. Human PON2-gene at 7q 21.3: cloning, multiple mRNA forms, and missense polymorphism in the coding sequence. Gene 1998; 213:149-157. (Pubitemid 28284734)
21. Standiford TJ. On the physiological role(s) of the paraoxonasese. Chemico-Biol Interac 1999; 120:379-388.
22. Ng CJ, Shi DM, Hama SY, et al. The paraoxonase gene family and atherosclerosis. Free Radic Biol Med 2005; 38:153-163. (Pubitemid 39656127)
23. Sorenson RC, Bisgaier CL, Aviram M, et al. Human serum paraoxonase/ arylesterases retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-1 stabilizes activity. Arterioscler Thromb Vasc Biol 1999; 19:2214-2225. (Pubitemid 29422255)
24. Harel M, Aharoni A, Gaidukov L, et al. Structure and evolution of the serum paraoxonase family of detoxifying and antiatherosclerotic enzymes. Nat Struct Mol Biol 2004; 11:412-419. (Pubitemid 38568944)
25. Moghtaderi A, Hashemi M, Dabiri S, et al. Serum paraoxonase and arylesterase activities in patients with lacunar infarction: a case control study. Clin Biochem 2011; 44:288-292.
26. Marsillach J, Aragonè s G, Mackness B, et al. Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment. Lipids Health Dis 2010; 9:46.
27. Draganov DI, La Du BN. Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch Pharmacol 2004; 369:78-88. (Pubitemid 38161225)
28. Gupta N, Gill K, Singh S. Paraoxonases: structure, gene polymorphismand role in coronary artery disease. Indian J Med Res 2009; 130:361-368.
29. Davies HG, Richter RJ, Keifer M, et al. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996; 14:334-336.
30. James RW, Leviev I, Ruiz J, et al. Promoter polymorphism T(107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes 2000; 49:1390-1393. (Pubitemid 30624241)
31. Blatter-Garin MC, James RW, Dussoix P, et al. Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 2007; 99:62-66.
32. Richter RJ, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999; 9:745-753. (Pubitemid 30011938)
33. Brophy VH, Jampsa RL, Clendenning JB, et al. Effects of 5 regulatoryregion polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 2001; 68:1428-1436. (Pubitemid 32510618)
34. Rainwater DL, Rutherford S, Dyer TD, et al. Determinants of variation inhuman serum paraoxonase activity. Heredity 2009; 102:147-154.
35. Leviev I, James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000; 20:516-520.
36. Leviev I, Negro F, James RW. Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol 1997; 17:2935-2939.
37. Brophy VH, Hastings MD, Clendenning JB, et al. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 2001; 11:77-84. (Pubitemid 32108664)
38. Deakin S, Leviev I, Brulhart-Meynet MC, et al. Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position 107 implicating the Sp1 transcription factor. Biochem J 2003; 372:643-649. (Pubitemid 36723911)
39. Suehiro T, Nakamura T, Inoue M, et al. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 2000; 150:295-298. (Pubitemid 30336541)
40. Mohamed Ali S, Chia SE. Interethnic variability of plasma paraoxonase (PON1) activity towards organophosphates and PON1 polymorphisms among Asian populationsa short review. Industrial Health 2008; 46:309-317.
41. Brophy VH, Jarvik GP, Furlong CE. PON1 polymorphisms. In Costa LG, Furlong CE, editors. Paraoxonase (PON1) in health and disease: basic and clinical aspects. Norwell, MA: Kluwer Academic Publishers; 2002. pp. 53-77.
42. Sen-Banerjee S, Siles X, Campos H. Tobacco smoking modifies association between Gln-Arg192 polymorphism of human paraoxonase gene and risk of myocardial infarction. Arterioscler Thromb Vasc Biol 2000; 20:2120-2126.
43. Costa LG, Cole TB, Jarvik GP, Furlong CE. Functional genomics of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 2003; 54:371-392. (Pubitemid 37386402)
44. Barter PJ, Rye K-A. Cholesteryl ester transfer protein, high density lipoprotein and arterial disease. Curr Opin Lipidol 2001; 12:377-382. (Pubitemid 32675497)
45. Gordon DJ, Probstfield JL, Garrison RJ. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79:8-15. (Pubitemid 19043669)
46. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006; 58:342-374. (Pubitemid 44394906)
47. Mackness MI, Arrol S, Abbott CA, Durrington PN. Protection of lowdensity lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104:129-135. (Pubitemid 24035640)
48. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96:2882-2891.
49. Lusis AJ. Atherosclerosis. Nature 2000; 407:233-241.
50. Mackness B, Durrington PN, Mackness MI. Lack of protection against oxidative modification of LDL by avian HDL. Biochem Biophys Res Commun 1998; 247:443-446. (Pubitemid 28420844)
51. Mackness B, Hine D, Liu Y, et al. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun 2004; 318:680-683. (Pubitemid 38624207)
52. Aviram M, Rosenblat M, Bisgaier CL, et al. Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest 1998; 101:1581-1590. (Pubitemid 28198486)
53. Rosenblat M, Coelman R, Aviram M. Increased macrophage glutathione content reduces cell-mediated oxidation of LDL and atherosclerosis in apolipoprotein E deficient mice. Atherosclerosis 2002; 163:17-28. (Pubitemid 34615722)
54. Rosenblat M, Aviram M. Oxysterols-induced activation of macrophage NADPH oxidase enhances cell-mediated oxidation of LDL in the atherosclerotic apolipoprotein E deficient mouse: inhibitory role for vitamin E. Atherosclerosis 2002; 100:69-80. (Pubitemid 34076644)
55. Rozenberg O, Shih DM, Aviram M. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 2005; 181:9-18. (Pubitemid 40804688)
56. Rosenblat M, Vaya J, Shih D, Aviram M. Paraoxonase 1 (PON1) enhances HDL mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Atherosclerosis 2005; 179:69-77. (Pubitemid 40249787)
57. Rosenblat M, Oren R, Aviram M. Lysophosphatidylcholine (LPC) attenuates macrophage-mediated oxidation of LDL. Biochem Biophys Res Commun 2006; 344:1271-1277.
58. Tavori H, Rosenblat M, Vaya J, Aviram M. Paraoxonase 1 interactions with atherosclerotic lesions and arterial macrophages protect against foam cell formation and atherosclerosis development. Clin Lipidol 2010; 5:685-697.
59. Tward A, Xia YR, Wang XP, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002; 106:484-490. (Pubitemid 34803695)
60. Oda MN, Bielicki JK, Ho TT, et al. Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. Biochem Biophys Res Commun 2002; 290:921-927. (Pubitemid 34687449)
61. Mackness B, Quarck R, Verreth W, et al. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 26:1545-1550. (Pubitemid 44288981)
62. Humbert R, Adler DA, Disteche CM, et al. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993; 3:73-76. (Pubitemid 23063292)
63. Richter RJ, Jarvik GP, Furlong CE. Paraoxonase 1 status as a risk factor for disease or exposure. Adv Exp Med Biol 2010; 660:29-35.
64. Wang M, Lang X, Zou L, et al. Four genetic polymorphisms of paraoxonase gene and risk of coronary heart disease: a meta-analysis based on 88 case-control studies. Atherosclerosis 2011; 214:377-385.
65. Wheeler JG, Keavney BD, Watkins H, et al. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 2004; 363:689-695. (Pubitemid 38296555)
66. Ikeda Y, Inoue M, Suehiro T, et al. Low human paraoxonase predicts cardiovascular events in Japanese patients with type 2 diabetes. Acta Diabetol 2009; 46:239-242.
67. Martinelli N, Girelli D, Olivieri O, et al. Novel serum paraoxonase activity assays are associated with coronary artery disease. Clin Chem Lab Med 2009; 47:432-440.
68. Mackness M, Mackness B. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important? Free Rad Biol Med 2004; 37:1317-1323.
69. Jarvik GP, Rozek LS, Brophy VH, et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1192 or PON155 genotype. Arterioscler Thromb Vasc Biol 2000; 20:2441-2447.
70. Qi L, Lu Z, Dong YH. The association of Paraoxonase-1 192Gln/Arg and Paraoxonase-2 311Cys/Ser gene polymorphisms with macrovascular disease in type 2 diabetes mellitus patients. Chin J Atheroscler 2007; 15:703-709.
71. Baum L, Ng HK, Woo KS, et al. Paraoxonase 1 gene Q192R polymorphism affects stroke and myocardial infarction risk. Clin Biochem 2006; 39:191-195.
72. Blatter Garin MC, Moren X, James RW. Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I. J Lipid Res 2006; 47:515-520. (Pubitemid 43345592)
73. Qin Q, Li YL, Zhao FM, et al. Association of paraoxonase polymorphisms and serum homocysteine thiolactone complex with coronary heart disease. Zhonghua Xin Xue Guan Bing Za Zhi 2006; 34:803-807.
74. Kotur-Stevuljevic J, Spasic S, Stefanovic A, et al. Paraoxonase-1 (PON1) activity, but not PON1 (Q192R) phenotype, is a predictor of coronary artery disease in a middle-aged Serbian population. Clin Chem Lab Med 2006; 44:1206-1213. (Pubitemid 44580802)
75. Ameno K, Ameno S, Kinoshita H, et al. Autopsy and postmortem examination case study on genetic risk factors for cardiac death: polymorphisms of endothelial nitric oxide synthase gene Glu298Asp variant and T-786C mutation, human paraoxonase 1 (PON1) gene and alpha2beta-adrenergic receptor gene. Vojnosanit Pregl 2006; 63:357-361.
76. Rios DL, DOnofrio LO, Cerqueira CC, et al. Paraoxonase 1 gene polymorphisms in angiographically assessed coronary artery disease: evidence for gender interaction among Brazilians. Clin Chem Lab Med 2007; 45:874-878. (Pubitemid 47041881)
77. Saeed M, Perwaiz Iqbal M, Yousuf FA, et al. Interactions and associations of paraoxonase gene cluster polymorphisms with myocardial infarction in a Pakistani population. Clin Genet 2007; 71:238-244. (Pubitemid 46322662)
78. Guxens M, Tomas M, Elosua R, et al. Association between paraoxonase-1 and paraoxonase-2 polymorphisms and the risk of acute myocardial infarction. Rev Esp Cardiol 2008; 61:269-275. (Pubitemid 351928300)
79. Jalilian A, Javadi E, Akrami M, et al. Association of cys 311 ser polymorphism of paraoxonase-2 gene with the risk of coronary artery disease. Arch Iran Med 2008; 11:544-549.
80. Ozkok E, Aydin M, Babalik E, et al. Combined impact of matrix metalloproteinase-3 and paraoxonase 1 55/192 gene variants on coronary artery disease in Turkish patients. Med Sci Monit 2008; 14:CR536-CR542.
81. Gamboa R, Regalado JC, Huesca-Gomez C, et al. Low paraoxonase and arylesterase plasma activities in Mexican patients with coronary artery disease. Arch Cardiol Mex 2008; 78:360-368.
82. Najafi M, Gohari LH, Firoozrai M. Paraoxonase 1 gene promoter polymorphisms are associated with the extent of stenosis in coronary arteries. Thromb Res 2009; 123:503-510.
83. Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008; 299:1265-1276. (Pubitemid 351439073)
84. Balcerzyk A, Zak I, Krauze J. Protective effect of R allele of PON1 gene on the coronary artery disease in the presence of specific genetic background. DisMarkers 2008; 24:81-88.
85. Troughton JA, Woodside JV, Yarnell JW, et al. Paraoxonase activity and coronary heart disease risk in healthy middle-aged males: the PRIME study. Atherosclerosis 2008; 197:556-563. (Pubitemid 351417899)
86. Aydin M, Gokkusu C, Ozkok E, et al. Association of genetic variants in methylenetetrahydrofolate reductase and paraoxonase-1 genes with homocysteine, folate and vitamin B12 in coronary artery disease. Mol Cell Biochem 2009; 325:199-208.
87. Mendonca MI, Dos Reis RP, Freitas AI, et al. Gene-gene interaction affects coronary artery disease risk. Rev Port Cardiol 2009; 28:397-415.
88. Katakami N, Sakamoto K, Kaneto H, et al. Cumulative effect of oxidative stressrelated gene polymorphisms on myocardial infarction in type 2 diabetes. Diabetes Care 2009; 32:e55.
89. Izar MC, Helfenstein T, Ihara SS, et al. Association of lipoprotein lipase D9N polymorphism with myocardial infarction in type 2 diabetes: the genetics, outcomes, and lipids in type 2 diabetes (GOLD) study. Atherosclerosis 2009; 204:165-170.
90. Taskiran P, Cam SF, Sekuri C, et al. The relationship between paraoxanase gene Leu-Met (55) and Gln-Arg (192) polymorphisms and coronary artery disease. Turk Kardiyol Dern Ars 2009; 37:473-478.
91. Agrawal S, Tripathi G, Prajnya R, et al. Paraoxonase 1 gene polymorphisms contribute to coronary artery disease risk among north Indians. Indian J Med Sci 2009; 63:335-344.
92. Birjmohun RS, Vergeer M, Stroes ES, et al. Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPICNorfolk Prospective Population Study. PLoS One 2009; 4:e6809.
93. Mohamed RH, Mohamed RH, Karam RA, Abd El-Aziz TA. The relationship between paraoxonase1-192 polymorphism and activity with coronary artery disease. Clin Biochem 2010; 43:553-558.
94. Mukamal KJ, Pai JK, Jensen MK, Rimm EB. Paraoxonase 1 polymorphisms and risk of myocardial infarction in women and men. Circ J 2009; 73:1302-1307.
95. Koubaa N, Nakbi A, Hammami S, et al. Association of homocysteine thiolactonase activity and PON1 polymorphisms with the severity of acute coronary syndrome. Clin Biochem 2009; 42:771-776.
96. Kaman D, Ilhan N, Metin K, et al. A preliminary study of human paraoxonase and PON 1 L/M55-PON 1 Q/R 192 polymorphisms in Turkish patients with coronary artery disease. Cell Biochem Funct 2009; 27:88-92.
97. Zhou H, Lu CZ, Gao Y, et al. Relationships between PON1 L55M polymorphism and coronary heart diseases complicated with fasting hyperglycemia in Han populations in Guangdong. Sichuan Da Xue Xue Bao Yi Xue Ban 2009; 40:68-72.
98. van Himbergen TM, van der Schouw YT, Voorbij HA, et al. Paraoxonase (PON1) and the risk for coronary heart disease and myocardial infarction in a general population of Dutch women. Atherosclerosis 2008; 199:408-414.
99. Lakshmy R, Ahmad D, Abraham RA, et al. Paraoxonase gene Q192R and L55M polymorphisms in Indians with acute myocardial infarction and association with oxidized low density lipoprotein. Indian J Med Res 2010; 131:522-529.
100. Wang Y, Luk AO, Ma RC, et al. Independent predictive roles of eotaxin Ala23Thr, paraoxonase 2 Ser311Cys and beta-adrenergic receptor Trp64Arg polymorphisms on cardiac disease in type 2 diabetes: an 8-year prospective cohort analysis of 1297 patients. Diabet Med 2010; 27:376-383.
101. Gluba A, Pietrucha T, Banach M, et al. The role of polymorphisms within paraoxonases (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the modulation of cardiovascular risk: a pilot study. Angiology 2010; 61:157-165.
102. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci (Lond) 2004; 107:435-447. (Pubitemid 39506735)
103. Sezer ED, Sozmen EY, Nart D, Onat T. Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation. Vasc Health Risk Manag 2011; 7:333-343.
104. Bolayirli IM, Aslan M, Balci H, et al. Effects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine. Life Sci 2007; 81:121-127. (Pubitemid 46921173)
105. Harangi M, Seres I, Varga Z, et al. Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage. Eur J Clin Pharmacol 2004; 60:685-691.
106. Kural BV, Orem C, Uydu HA, et al. The effects of lipid lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia. Coron Artery Dis 2004; 15:277-283. (Pubitemid 39061612)
107. Tsimihodimos V, Karabina SAP, Tambaki AP, et al. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIa and type IIb. Arterioscler Throm Vasc Biol 2002; 22:306-311. (Pubitemid 34127044)
108. Dullaart RPF, de Vries R, Voorbij HAM, et al. Serum paraoxonase- 1 activity is unaffected by short term administration of simvastin, bezafibrate, and their combination in type 2 diabetes mellitus. Eur J Clin Invest 2009; 39:200-203.
109. Balogh Z, Fülop P, Seres I, et al. Effects of simvastatin on serum paraoxonase activity. Clin Drug Invest 2001; 21:505-510. (Pubitemid 32681922)
110. Paragh G, Töröcsik D, Seres I, Harangi M. Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia. Curr Med Res Opin 2004; 20:1321-1327. (Pubitemid 39120797)
111. Fuhrman B, Koren L, Volkova N, et al. Atorvastatin therapy in hypercholesterolemic patients suppressed cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis 2002; 64:179-185. (Pubitemid 34765651)
112. Ota K, Suehiro T, Arii K, et al. Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene. Metabolism 2005; 54:142-150. (Pubitemid 40174840)
113. Deakin S, Leviev I, Guernier S, James RW. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase. A role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol 2003; 23:2083-2089. (Pubitemid 37433204)
114. Gouedard C, Koum-Besson N, Barouki R, et al. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol Pharmacol 2003; 63:945-956. (Pubitemid 36369002)
115. Deakin SP, Guernier S, James RW. Pharmacogenetic interaction between paraoxonase-1 gene promoter polymorphismC-107T and statin. Pharmacogenet Genom 2007; 17:451-457. (Pubitemid 46763390)
116. Tomas M, Senti M, Garcia-Faria F, et al. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patient. Arterioscler Thromb Vasc Biol 2000; 20:2113-2119.
117. Nagila A, Permpongpaiboon T, Tantrarongroj S, et al. Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status. Pharmacol Rep 2009; 61:892-898.
118. Mirdamadi HZ, Sztanek F, Derdak Z, Paragh G. The human paraoxonase- 1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. Br J Clin Pharmacol 2008; 66:366-374.
119. Durrington PN, Mackness MI, Bhatnagar D, et al. Effects of two different fibric acid derivates on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type Iib hyperlipoproteinaemia. Atherosclerosis 1998; 138:217-225. (Pubitemid 28255170)
120. Turay J, Grnakova V, Valka J. Changes in paraoxonase and apolipoprotein A-I, B, C-III and E in subjects with combined familial hyperlipoproteinaemia treated with ciprofibrate. Drug Exp Clin Res 2000; 26:83-88. (Pubitemid 30479602)
121. Paragh G, Balogh Z, Seres I, et al. Effect of gemfibrozil on HDLassociated serum paraoxonase activity and lipoprotein profile in patients with hyperlipidaemia. Clin Drug Invest 2000; 19:277-282. (Pubitemid 30216001)
122. Paragh G, Seres I, Balogh Z, et al. The effect of micronised fenofibrate on serum paraoxonase activity in patients with coronary heart disease. Diab Met 2003; 29:613-618. (Pubitemid 38082164)
123. Balogh Z, Seres I, Harangi M, Kovacs P, Kakuk G, Paragh G. Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of beneficial action of fibrates? Diab Met 2001; 27:604-610. (Pubitemid 33051711)
124. Noto H, Kawamura M, Hashimoto Y, et al. Modulation of HDL metabolism by probucol in complete cholesteryl ester transfer protein deficiency. Atherosclerosis 2003; 171:131-136. (Pubitemid 37464638)
125. Hong SC, Zhao SP, Wu ZH. Probucol up-regulates paraoxonase 1 expression in hepatocytes of hypercholesterolemic rabbits. J Cardiovasc Pharmacol 2006; 47:77-81.
126. Jaichander P, Selvarajan K, Garelnabi M, et al. Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J Lipid Res 2008; 49:2142-2148.
127. Audikovszky M, Pados G, Seres I, et al. Orlistat increases serum paraoxonase activity in obese patients. Nutr Metab Cardiovasc Dis 2007; 17:268-273. (Pubitemid 46551690)
128. Turfaner N, Uzun H, Balci H, et al. Ezetimibe therapy and its influence on oxidative stress and fibrinolytic activity. South Med J 2010; 103:428-433.
129. Uzar E, Acar A, Evliyaog? lu O, et al. The antioxidant and antiapoptotic effects of nebivolol and zofenopril in a model of cerebral ischemia/ reperfusion in rats. Prog Neuropsychopharmacol Biol Psych 2011; 36:22-28.
130. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84:891-896.
131. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409:202-207. (Pubitemid 32144286)
132. Bouman HJ, Schomig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011; 17:110-116.
133. Sibbing D, Koch W, Massberg S, Schomig A, Kastrati A. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 2011; 32:1605-1613.
134. Trenk D, Hochholzer W, Fromm MF, et al. J. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. Circ Cardiovasc Genet 2011; 4:429-436.
135. Fontana P, James R, Barazer I, et al. Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study. J Thromb Haemost 2011; 9:1664-1666.
136. Rideg O, Komocsi A, Magyarlaki T, et al. Impact of genetic variants on postclopidogrel platelet reactivity in patients after elective percutaneous coronary intervention. Pharmacogenomics 2011; 12:1269-1280.
137. Lewis JP, Fisch AS, Ryan K, et al. Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response. Clin Pharmacol Ther 2011; 90:568-574.
138. Campo G, Ferraresi P, Marchesini J, et al. Relationship between paraoxonase Q192R gene polymorphism and on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention. J Thromb Haemos 2011; 9:2106-2108.
139. Cuisset T, Morange PE, Quilici J, et al. Paraoxonase-1 and clopidogrel efficacy. Nat Med 2011; 17:1039.
140. Simon T, Steg PG, Becquemont L, et al. Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction. Clin Pharmacol Ther 2011; 90:561-567.
141. Dansette PM, Rosi J, Bertho G, Mansuy D. Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. Chem Res Toxicol 2012; 25:348-356.
142. Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 2005; 69:541-550.
143. Costa LG, Giordano C, Furlong CE. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol 2011; 81:337-344.
144. Pre court L-P, Amre D, Denis M-C, et al. The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis 2011; 214:20-36.
145. Shih DM, Gu L, Hama S, et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996; 97:1630-1639. (Pubitemid 26105474)
146. Mackness MI, Bouiller A, Hennuyer N, et al. Paraoxonase activity is reduced in pro-atherosclerotic diet in rabbits. Biochem Biophys Res Commun 2000; 269:232-236. (Pubitemid 30440282)
147. Sutherland WHF, Walker RJ, de Jong SA, et al. Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat. Arterioscler Thromb Vasc Biol 1999; 19:1340-1347. (Pubitemid 29227656)
148. Tomas M, Senti M, Elosua R, et al. Interaction between the Gln-Arg 192 variants of the paraoxonase gene and oleic acid intake as a determinant of high-density lipoprotein cholesterol and paraoxonase activity. Eur J Pharmacol 2001; 432:121-128. (Pubitemid 34003591)
149. Nguyen SD, Sok DE. Beneficial effect of oleoylated lipids on paraoxonase 1: protection against oxidative inactivation and stabilization. Biochem J 2003; 375:275-285. (Pubitemid 37315435)
150. Gouedard C, Barouki R, Morel Y. Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor dependent mechanism. Mol Cell Biol 2004; 24:5209-5222. (Pubitemid 38738157)
151. Mahrooz A, Rashidi M-R, Nouri M. Naringenin is an inhibitor of human serum paraoxonase (PON1): an in vitro study. J Clin Lab Anal 2011; 25:395-401.
152. Khateeb J, Gantman A, Kreitenberg AJ, et al. Paraoxonase 1 (PON1) expression in hepatocytes is upregulated by pomegranate polyphenols: a role for
153. Rock W, Rosenblat M, Miller-Lotan R, et al. Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities. J Agric Food Chem 2008; 56:8704-8713.
154. Boesch-Saadatmandi C, Egert S, Schrader C, et al. Effect of quercetin on paraoxonase 1 activity: studies in cultured cells, mice and humans. J Physiol Pharmacol 2010; 61:99-105.
155. Ferre N, Camps J, Fernandez-Ballart J, et al. Regulation of serum paraoxonase activity by genetic, nutritional and lifestyle factors in the general population. Clin Chem 2003; 49:1491-1497. (Pubitemid 37011737)
156. Kleemola P, Freese R, Jaulainen M, et al. Dietary determinants of serum paraoxonase activity in healthy humans. Atherosclerosis 2002; 160:425-432. (Pubitemid 34159337)
157. Rantala M, Silaste ML, Tuominen A, et al. Dietary modifications and gene polymorphisms alter serum paraoxonase activity in healthy women. J Nutr 2002; 132:3012-3017.
158. Isik B, Ceylan A, Isik R. Oxidative stress in smokers and nonsmokers. Inhal Toxicol 2007; 19:767-769.
159. Mouhamed DH, Ezzaher A, Araoud M, et al. Paraoxonase 1 (PON1) activity and lipid parameters in Tunisian smokers. Ann Biol Clin (Paris) 2010; 68:143-147.
160. Solak ZA, Kabaroglu C, Cok G, et al. Effect of different levels of cigarette smoking on lipid peroxidation, glutathione enzymes and paraoxonase 1 activity in healthy people. Clin Exp Med 2005; 5:99-105. (Pubitemid 41597268)
161. Senti M, Aubo C, Tomas M. Differential effects of smoking on myocardial infarction risk according to the Gln/Arg 192 variants of the human paraoxonase gene. Metabolism 2000; 49:557-559. (Pubitemid 30305249)
162. Nishio E, Watanabe Y. Cigarette smoke extracts inhibits plasma paraoxonase activity by modification of the enzymes free thiols. Biochem Biophys Res Comm 1997; 236:289-293. (Pubitemid 27373286)
163. Rao MN, Marmillot P, Gong M, et al. Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans. Metabolism 2003; 52:1287-1294. (Pubitemid 37351096)
164. Osaki F, Ikeda Y, Suehiro T, et al. Roles of Sp1 and protein kinase C in regulation of human serum paraoxonase 1 (PON1) gene transcription in HepG2 cells. Atherosclerosis 2004; 176:279-287. (Pubitemid 39369517)
165. Gharakhanlou R, Afzalpour ME, Gaeini AA, Rahnama N. Effects of aerobic exercises on the serum paraoxonase 1/arylesterase activity and lipid profile in non-active healthy men. Int J Sports Sci Eng 2007; 1:105-112.
166. Permpongpaiboon T, Nagila A, Pidetcha P, et al. Decreased paraoxonase 1 activity and increased oxidative stress in low lead-exposed workers. Hum Exp Toxicol 2011; 30:1196-1203.
167. Selek S, Aslan M, Horoz M, et al. Oxidative status and serum PON1 activity in beta-thalassemia minor. Clin Biochem 2007; 40:287-291.
168. Senti M, Tomas M, Anglada R, et al. Inter-relationship of smoking, paraoxonase activity, and leisure time physical activity: a populationbased study. Eur J Int Med 2003; 14:178-184. (Pubitemid 36677614)
169. Goldhammer E, Ben-Sira D, Zaid G, et al. Paraoxonase activity following exercise-based cardiac rehabilitation program. J Cardiopulm Rehabil Prev 2007; 27:151-154. (Pubitemid 47424609)
170. Seres I, Paragh G, Deschene E, et al. Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp Gerontol 2004; 39:59-66. (Pubitemid 38068260)
171. Winnier DA, Rainwater DL, Cole SA, et al. Sex-specific QTL effects on variation in paraoxonase 1 (PON1) activity in Mexican Americans. Genet Epidemiol 2007; 31:66-74. (Pubitemid 46033532)
172. Xhyheri B, Bugiardini R. Diagnosis and treatment of heart disease: are women different from men? Prog Cardiovasc Dis 2010; 53:227-236.
173. Pizzi C, Bugiardini R. Further insights into syndrome X. Heart 2010; 96:1865-1867.
174. Sklan EH, Lowenthal A, Korner M, et al. Acetylcholinesterase/ paraoxonase genotype and expression predict anxiety scores in Health, Risk Factors, Exercise Training, and Genetics study. Proc Natl Acad Sci USA 2004; 101:5512-5517. (Pubitemid 38481188)